Ensysce Biosciences Launches Pivotal Phase 3 Study of PF614, Aiming to Redefine Pain Therapy with Reduced Abuse Risk

Reuters07-16

Ensysce Biosciences Launches Pivotal Phase 3 Study of PF614, Aiming to Redefine Pain Therapy with Reduced Abuse Risk

Ensysce Biosciences Inc., a clinical-stage pharmaceutical company, has announced the commencement of a pivotal Phase 3 study for its lead product candidate, PF614. This next-generation opioid is designed to provide effective pain relief while minimizing the risk of abuse. The study, titled PF614-301, is a multicenter, randomized, double-blind, placebo- and active-controlled trial aimed at evaluating the efficacy and safety of PF614 in treating moderate to severe pain following abdominoplasty surgery. Ensysce has partnered with Rho, Inc., a Clinical Research Organization with expertise in CNS disorders and pain studies, to conduct this trial. The results of this study are yet to be presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1049119) on July 16, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2551140713?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-16 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551140713","market":"nz","top_or_hot":-1,"title":"Ensysce Biosciences Launches Pivotal Phase 3 Study of PF614, Aiming to Redefine Pain Therapy with Reduced Abuse Risk","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ensysce Biosciences Launches Pivotal Phase 3 Study of PF614, Aiming to Redefine Pain Therapy with Reduced Abuse Risk\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ENSC\">Ensysce Biosciences Inc.</a>, a clinical-stage pharmaceutical company, has announced the commencement of a pivotal Phase 3 study for its lead product candidate, PF614. This next-generation opioid is designed to provide effective pain relief while minimizing the risk of abuse. The study, titled PF614-301, is a multicenter, randomized, double-blind, placebo- and active-controlled trial aimed at evaluating the efficacy and safety of PF614 in treating moderate to severe pain following abdominoplasty surgery. Ensysce has partnered with Rho, Inc., a Clinical Research Organization with expertise in CNS disorders and pain studies, to conduct this trial. The results of this study are yet to be presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ENSCW\">Ensysce Biosciences Inc.</a> published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1049119) on July 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ensysce Biosciences Launches Pivotal Phase 3 Study of PF614, Aiming to Redefine Pain Therapy with Reduced Abuse Risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnsysce Biosciences Launches Pivotal Phase 3 Study of PF614, Aiming to Redefine Pain Therapy with Reduced Abuse Risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-16 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ensysce Biosciences Launches Pivotal Phase 3 Study of PF614, Aiming to Redefine Pain Therapy with Reduced Abuse Risk\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ENSC\">Ensysce Biosciences Inc.</a>, a clinical-stage pharmaceutical company, has announced the commencement of a pivotal Phase 3 study for its lead product candidate, PF614. This next-generation opioid is designed to provide effective pain relief while minimizing the risk of abuse. The study, titled PF614-301, is a multicenter, randomized, double-blind, placebo- and active-controlled trial aimed at evaluating the efficacy and safety of PF614 in treating moderate to severe pain following abdominoplasty surgery. Ensysce has partnered with Rho, Inc., a Clinical Research Organization with expertise in CNS disorders and pain studies, to conduct this trial. The results of this study are yet to be presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ENSCW\">Ensysce Biosciences Inc.</a> published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1049119) on July 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nNDL8pFzLV:1","article_id":"2551140713","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551140713","pubTimestamp":1752667233,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ensysce Biosciences Inc., a clinical-stage pharmaceutical company, has announced the commencement of a pivotal Phase 3 study for its lead product candidate, PF614. This next-generation opioid is designed to provide effective pain relief while minimizing the risk of abuse. The study, titled PF614-301, is a multicenter, randomized, double-blind, placebo- and active-controlled trial aimed at evaluating the efficacy and safety of PF614 in treating moderate to severe pain following abdominoplasty surgery. Ensysce has partnered with Rho, Inc., a Clinical Research Organization with expertise in CNS disorders and pain studies, to conduct this trial. The results of this study are yet to be presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advic","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ENSC":"Ensysce Biosciences Inc."},"translate_title":"Ensysce Biosciences启动PF614关键3期研究，旨在重新定义疼痛疗法，降低滥用风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENSC":0.9},"content_text":"Ensysce Biosciences Launches Pivotal Phase 3 Study of PF614, Aiming to Redefine Pain Therapy with Reduced Abuse Risk\n    \n\nEnsysce Biosciences Inc., a clinical-stage pharmaceutical company, has announced the commencement of a pivotal Phase 3 study for its lead product candidate, PF614. This next-generation opioid is designed to provide effective pain relief while minimizing the risk of abuse. The study, titled PF614-301, is a multicenter, randomized, double-blind, placebo- and active-controlled trial aimed at evaluating the efficacy and safety of PF614 in treating moderate to severe pain following abdominoplasty surgery. Ensysce has partnered with Rho, Inc., a Clinical Research Organization with expertise in CNS disorders and pain studies, to conduct this trial. The results of this study are yet to be presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1049119) on July 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2551140713","isCrawlerRequest":true}